Serafín-Higuera Idanya, Garibay-Cerdenares Olga Lilia, Illades-Aguiar Berenice, Flores-Alfaro Eugenia, Jiménez-López Marco Antonio, Sierra-Martínez Pavel, Alarcón-Romero Luz Del Carmen
Laboratorio de Citopatología e Histoquímica, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero México.
Laboratorio de Biomedicina Molecular, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero México.
Proteome Sci. 2016 Sep 5;14(1):10. doi: 10.1186/s12953-016-0099-4. eCollection 2016.
Cervical cancer (CC) is the fourth most common cancer in women worldwide with an estimated 528,000 new cases in 2012. The same year México had an incidence of 13,960 and a mortality of 4769 cases. There are several diagnosis methods of CC; among the most frequents are the conventional Pap cytology (Pap), colposcopy, and visual inspection with acetic acid (VIA), histopathological examination, tests of imaging and detection of high-risk papilloma virus (HR-HPV) with molecular tests (PCR, hybridization, sequencing). Proteomics is a tool for the detection of new biomarkers that can be associated with clinical stage, histological type, prognosis, and/or response to treatment. In this study we performed a comparative analysis of CC cells with normal cervical cells. The proteomic analysis was carried out with the fluorescent two-dimensional electrophoresis (2D-DIGE) technique to subsequently identify differential protein profiles using Decyder Software, and the selected proteins were identified by Mass Spectrometry (MALDI-TOF).
The proteins that showed an increased expression in cervical cancer in comparison with normal cervix cells were: Mimecan, Actin from aortic smooth muscle and Lumican. While Keratin, type II cytoskeletal 5, Peroxiredoxin-1 and 14-3-3 protein sigma showed a decrease in their protein expression level in cervical cancer in comparison with normal cervix cells.
Thus, this study was successful in identifying biomarker signatures for cervical cancer, and might provide new insights into the mechanism of CC progression.
宫颈癌(CC)是全球女性中第四大常见癌症,2012年估计有52.8万新发病例。同年,墨西哥的发病率为13960例,死亡率为4769例。宫颈癌有多种诊断方法;最常用的方法包括传统巴氏细胞学检查(Pap)、阴道镜检查、醋酸肉眼观察(VIA)、组织病理学检查、影像学检查以及通过分子检测(PCR、杂交、测序)检测高危乳头瘤病毒(HR-HPV)。蛋白质组学是一种用于检测可与临床分期、组织学类型、预后和/或治疗反应相关的新生物标志物的工具。在本研究中,我们对宫颈癌细胞与正常宫颈细胞进行了比较分析。采用荧光二维电泳(2D-DIGE)技术进行蛋白质组分析,随后使用DeCyder软件鉴定差异蛋白质谱,并通过基质辅助激光解吸电离飞行时间质谱(MALDI-TOF)鉴定所选蛋白质。
与正常宫颈细胞相比,在宫颈癌中表达增加的蛋白质有: mimecan、主动脉平滑肌肌动蛋白和核纤蛋白。而角蛋白II型细胞骨架5、过氧化物酶1和14-3-3蛋白σ在宫颈癌中的蛋白质表达水平与正常宫颈细胞相比有所下降。
因此,本研究成功鉴定了宫颈癌的生物标志物特征,并可能为宫颈癌进展机制提供新的见解。